AML-251 Overall Survival (OS) With Intensive Chemotherapy (IC) vs Non-IC in Patients With Newly Diagnosed (ND) AML from the Connect® Myeloid Disease Registry Ineligible for Randomized Clinical Trials (RCT)

Harry P. Erba,Daniel A. Pollyea,Mikkael A. Sekeres,Guillermo Garcia-Manero,Karen Seiter, Irene S. DeGutis, Pavel Kiselev, Ali McBride, Edward Yu,Gail J. Roboz

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览1

暂无评分

摘要

Most patients with ND AML in the Connect® Myeloid Disease Registry would have been ineligible for VIALE-A due to being too fit or unfit. Among patients ineligible for an RCT due to unfitness, there was an association with increased OS in patients receiving IC vs those receiving venetoclax-based therapies.

查看译文

关键词

AML,acute myeloid leukemia,chemotherapy,eligibility criteria,overall survival,registry

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要